Tech Blog

Tempero Bio, Inc.

Last verified 2026-05-08. JSON

The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.

Total raised$77.0Mattributed
Latest roundFunding round, $77.0M, 2025-11-04attributed
Foundedunknown
HeadquartersOAKLAND, CA
Industrybio
Stageunknown
Websitetemperobio.com

Tempero Bio is a clinical-stage biopharma developing TMP-301, an oral mGluR5 modulator, to treat substance use disorders like cocaine and alcohol addiction. It serves patients with addiction and their clinicians, advancing into Phase 2. Its edge is dampening rather than blocking glutamate signaling, validated by PET occupancy.

Funding rounds

DateRoundAmountLead
2025-11-04Funding round$77.0Mundisclosed

Detected tech stack

Google Cloud CDN, Sentry, Partytown, Vercel Speed Insights, WebsiteBuilder, Wix, Google Cloud, React, lodash .

Provenance

FactStatusBasis
Funding round, $77.0Mattributedsec-edgar named as publisher. No document URL on file.
Total raised $77.0Mattributedsec-edgar named as publisher. No document URL on file.
Company existenceself-reportedtemperobio.com, read 2026-05-08
Descriptionself-reportedtemperobio.com, read 2026-05-08

Nothing on this page is sourced yet. A sourced fact links to a document that states it.

Change history

Date
2026-09-25Latest round: seed, $77.0M, 2025-11-04 → Funding round, $77.0M, 2025-11-04, sec-edgar, No document URL on file

Records begin 2026-09-24. All changes